Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.
Canyon Hopkins, PharmD
Advertisement
Articles by Canyon Hopkins, PharmD
Enfortumab vedotin-ejfv (Seagen; Padcev) is a first-in-class antibody-drug conjugate approved for patients with previously treated locally advanced or metastatic urothelial cancer.
Advertisement
Latest Updated Articles
Oncology Overview: Enfortumab vedotin-ejfv for Advanced or Metastatic Urothelial CancerPublished: September 24th 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
3
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
4
PCV20 Demonstrates Real-World Effectiveness Against Pneumonia in Older Adults
5
